SCHEMBL7204066

SCHEMBL7204066

NC(=O)N1CCC(S(=O)(=O)c2ccc(-c3ccc(Cl)cc3)cc2)C(O)(C(=O)O)C1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
MMP13 P45452 2/20 0.37
TRPV4 Q9HBA0 2/20 0.37
MGLL Q99685 2/20 0.37
ADAMTS4 O75173 1/20 0.37
MMP1 P03956 1/20 0.37
ADAMTS5 Q9UNA0 2/20 0.36
KMT2A Q03164 1/20 0.36
CNR1 P21554 2/20 0.36
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA7 P43166 2/20 0.36
CA9 Q16790 2/20 0.36
CA14 Q9ULX7 2/20 0.36
MMP8 P22894 4/20 0.35
MMP3 P08254 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7201014 0.91 SMN1; SMN2 (0.41) ALDH1A1GAAMMP13MMP1KMT2A
SCHEMBL7204544 0.90 MMP1 (0.41) ALDH1A1GAAMMP13MGLLADAMTS4
SCHEMBL7290273 0.90 MGLL (0.41) MMP13MGLLMMP1KMT2ACA12
SCHEMBL7300738 0.89 MMP13 (0.48) ALDH1A1GAAMMP13MMP1KMT2A
SCHEMBL7201540 0.89 ADAMTS4 (0.39) MMP13ADAMTS4MMP1ADAMTS5CA12
SCHEMBL7292292 0.86 AKR1C3 (0.45) ALDH1A1GAAMMP13ADAMTS4MMP1
SCHEMBL7205455 0.86 MMP9 (0.44) ALDH1A1MMP13MMP1ADAMTS5MMP8
SCHEMBL7205347 0.85 MMP1 (0.56) ALDH1A1MMP13ADAMTS4MMP1KMT2A
SCHEMBL7203105 0.84 MMP13 (0.38) MMP13MMP1CA12CA1CA2
SCHEMBL7205956 0.83 MMP13 (0.53) MMP13MMP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 ALDH1A1 1443/4885GAA 131/4885MMP13 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.